Literature DB >> 25279482

Successful treatment of Schnitzler syndrome with canakinumab.

Robbie Pesek1, Roger Fox.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25279482

Source DB:  PubMed          Journal:  Cutis        ISSN： 0011-4162


× No keyword cloud information.
  5 in total

Review 1.  Schnitzler Syndrome: a Review.

Authors:  L Gusdorf; D Lipsker
Journal:  Curr Rheumatol Rep       Date:  2017-08       Impact factor: 4.592

Review 2.  An expanding role for interleukin-1 blockade from gout to cancer.

Authors:  Charles Anthony Dinarello
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

3.  Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler's Syndrome.

Authors:  Vadim R Gorodetskiy; Svetlana O Salugina; Evgeny S Fedorov
Journal:  Case Rep Rheumatol       Date:  2018-04-11

4.  A Rare but Fascinating Disorder: Case Collection of Patients with Schnitzler Syndrome.

Authors:  Maaman Bashir; Brittany Bettendorf; Richard Hariman
Journal:  Case Rep Rheumatol       Date:  2018-03-08

Review 5.  Hereditary systemic autoinflammatory diseases and Schnitzler's syndrome.

Authors:  Mark Kacar; Shelly Pathak; Sinisa Savic
Journal:  Rheumatology (Oxford)       Date:  2019-11-01       Impact factor: 7.580
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.